Patients with cancer, kidney disease, and other ailments could pay higher drug prices for months longer than they otherwise would thanks to court delays caused by the coronavirus outbreak.
At least six patent infringement lawsuits over brand-name drugs are at risk of surpassing—or are already set to exceed—Food and Drug Administration timelines for approving generic versions, according to a Bloomberg Law analysis of court dockets. Depending on how long the pandemic goes on, that list could grow.
“Given the extraordinary circumstances we are in, it’s very likely there will be disruptions that will create a risk of delayed entry” of ...